Navigation Links
Established and Emerging Biotech Clusters

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Established and Emerging Biotech Clusters

There has been widespread interest in establishing geographically focused clusters of biotechnology companies and related organizations. It is important for all stakeholders to understand the capabilities of different clusters across the world. Careful alignment of location strategies with the strengths of the various clusters ensures that maximum value can be derived from participation. Understand the key components of a successful biotech cluster and the prevailing trends in biotech research that influence how clusters operate. Gain an overview of key decision making criteria when developing location strategies for research and development. Compare the most prominent areas of expertise within different clusters across the world and identify core strengths. Assess detailed profiles of 41 clusters in both established and emerging locations, and identify key participants and funding sources. View how clusters rank when scored by patenting activity, publications, company presence, industry-academia partnerships, and policy environment. The plentiful government funding, the mature VC sector, the favorable policy environment, and the strong entrepreneurial culture all make the US a leading destination for biotechnology research. The top three US clusters – namely San Francisco, San Diego, and Boston – outscore the rest of the established biotech clusters by a large margin. Among the emerging clusters, Australia's Melbourne cluster (ranked 24th overall) dominates the group, based on its favorable policy and regulatory environment, especially in clinical trials. The Melbourne cluster has also seen a high amount of collaborative activity with international pharmaceutical companies. VC funding is becoming difficult to obtain, especially for early stage companies. The total innovation capital decreased to $11.3bn in 2010, down by 19% compared with 2006. In addition, the upfront payment components of these financings have reduced by more than 54%, further shrinking the innovation capital available to start-up companies. How do the many biotech clusters of the world compare when ranked against each other? What are the key criteria that should be considered when choosing a location to conduct research in specific areas of drug discovery? What are the crucial components of a successful biotechnology cluster and what characteristics have led to serial innovation? What are the typical commercial rental rates likely to be charged within various biotech clusters across the world? Which are the most important academic institutions and companies in a particular region that present attractive opportunities for collaboration?

About the author



•Introduction to the biotech cluster concept

•Key trends in biotechnology research

•Established biotech clusters

•Emerging biotech clusters

Introduction to the biotech cluster concept



•Definition of a cluster

•Advantages of the cluster approach in biotechnology

- Productivity advantages

- Innovation advantages

- New business establishment advantages

•Components of a successful biotech cluster

- Strong science base

- Entrepreneurial culture

- Strong base of companies

- Effective scientific and business networks

- Ability to attract a skilled workforce

- Effective financing mechanisms

- Strong infrastructure and business support services

- Conducive regulatory and intellectual property environment

- Supportive policy environment

Key trends in biotechnology research



•Pharmaceutical organization trends

- Diversification of R&D

- Exploitation of academic resources in a strategic manner

•Research area trends

- Western clusters dominate, but emerging clusters have niche strengths

- Increasing importance of rare disease research

- Refocused attention on diseases of local relevance in emerging countries

•Cluster trends

- Governmental approaches to developing biotech industries via clusters

- Access to VC funding particularly difficult for early-stage companies

- Removal of regulatory hurdles in many emerging clusters

- Investment in technology transfer and commercialization mechanisms

Established biotech clusters



•Top 10 established biotech clusters

•Detailed cluster profiles

- US

- Canada

- Germany

- Switzerland

- UK

- France

- Sweden

- Belgium

- Israel

- Japan

Emerging biotech clusters



•Top 10 emerging biotech clusters

•Detailed cluster profiles

- Brazil

- United Arab Emirates (UAE)

- South Korea

- New Zealand

- Australia

- Singapore

- China

- Taiwan

- Russia

- India

- Malaysia





- Selection of clusters

- Geographical limit of clusters

- Definition of biotechnology


- Patenting activity score

- Publication score

- MeSH terms included for publication search in PubMed

- Company presence score

- Industry–academia partnership score

- Regulatory and policy environment score

•Full list of clusters assessed



- Chapter 1 Introduction to the biotech cluster concept

- Chapter 2 Key trends in biotechnology research

- Chapter 3 and Chapter 4 biotech cluster profiles


•Table: Chinese companies addressing local health needs

•Table: Indian companies addressing local health needs

•Table: The global top 10 established biotech clusters

•Table: San Francisco cluster scores

•Table: San Francisco cluster summary

•Table: San Diego cluster scores

•Table: San Diego cluster summary

•Table: Boston cluster scores

•Table: Boston cluster summary

•Table: Raleigh-Durham-Chapel Hill (Research Triangle) cluster scores

•Table: Raleigh-Durham-Chapel Hill (Research Triangle) cluster summary

•Table: Los Angeles cluster scores

•Table: Los Angeles cluster summary

•Table: Toronto cluster scores

•Table: Toronto cluster summary

•Table: British Columbia cluster scores

•Table: British Columbia cluster summary

•Table: Berlin cluster scores

•Table: Berlin cluster summary

•Table: Rhine Neckar Triangle cluster scores

•Table: Rhine Neckar Triangle cluster summary

•Table: Biovalley cluster scores

•Table: Biovalley cluster summary

•Table: Bioalps cluster scores

•Table: Bioalps cluster summary

•Table: Zurich cluster scores

•Table: Zurich cluster summary

•Table: Cambridge cluster scores

•Table: Cambridge cluster summary

•Table: London cluster scores

•Table: London cluster summary

•Table: Glasgow-Edinburgh-Dundee cluster scores

•Table: Glasgow-Edinburgh-Dundee cluster summary

•Table: Paris cluster scores

•Table: Paris cluster summary

•Table: Stockholm-Uppsala cluster scores

•Table: Stockholm-Uppsala cluster summary

•Table: Medicon Valley cluster scores

•Table: Medicon Valley cluster summary

•Table: Brussels cluster scores

•Table: Brussels cluster summary

•Table: Tel-Aviv cluster scores

•Table: Tel-Aviv cluster summary

•Table: Jerusalem cluster scores

•Table: Jerusalem cluster summary

•Table: Tokyo cluster scores

•Table: Tokyo cluster summary

•Table: Kansai cluster scores

•Table: Kansai cluster summary

•Table: The global top 10 emerging biotech clusters

•Table: Minas Gerais cluster scores

•Table: Minas Gerais cluster summary

•Table: São Paulo cluster scores

•Table: São Paulo cluster summary

•Table: Rio de Janeiro cluster scores

•Table: Rio de Janeiro cluster summary

•Table: Dubai cluster scores

•Table: Dubai cluster summary

•Table: Seoul cluster scores

•Table: Commercial products from biotechnology companies in Seoul

•Table: Seoul cluster summary

•Table: Auckland cluster scores

•Table: Auckland cluster summary

•Table: Melbourne cluster scores

•Table: Melbourne cluster summary

•Table: Brisbane cluster scores

•Table: Government investments in Queensland's biomedical research infrastructure

•Table: Brisbane cluster summary

•Table: Biopolis cluster scores

•Table: Biopolis cluster summary

•Table: Tuas cluster scores

•Table: Manufacturing presence of MNCs in Tuas Biomedical Park

•Table: Tuas cluster summary

•Table: R&D activities of large pharmaceutical companies in China

•Table: Beijing cluster scores

•Table: Beijing cluster summary

•Table: Shanghai cluster scores

•Table: Shanghai cluster summary

•Table: Taipei cluster scores

•Table: Taipei cluster summary

•Table: Moscow cluster scores

•Table: Moscow cluster summary

•Table: Bangalore cluster scores

•Table: Bangalore cluster summary

•Table: Mumbai cluster scores

•Table: Mumbai cluster summary

•Table: Hyderabad cluster scores

•Table: Hyderabad cluster summary

•Table: Malaysia cluster scores

•Table: Malaysia cluster summary

•Table: IPC codes used for patent searching

•Table: Rank and score for all established clusters

•Table: Rank and score for all emerging clusters

•Table: Other clusters assessed in the initial shortlist but not profiled


•Figure: Components of a successful biotech cluster

•Figure: US, Europe, and Canada funding for early-stage biotech ($bn), 2006–10

•Figure: US and Europe average upfront payments in biotech financing ($m), 2006–10

•Figure: VC investment in biotechnology in San Francisco ($m), 2000–10

•Figure: Hybritech serial entrepreneur effect

•Figure: VC funding for important US clusters ($bn), 2000–10

•Figure: Canada therapeutic development pipeline, 2010

•Figure: Switzerland creation of biotechnology start-ups, 2000–10

•Figure: London mix of biotechnology/pharmaceutical companies

•Figure: Therapy area focus of London-based life science companies

•Figure: Israel development stage of life science companies

•Figure: Jerusalem distribution of life science companies by business type

•Figure: Japan number of biotechnology start-ups, 2000–09

•Figure: India current regulatory process for recombinant DNA products

•Figure: Decision criteria for choosing an R&D location

Companies Mentioned

Alphapharm, Banco Santander, S.A., Bank of India, Becton, Dickinson and Company, Cambridge University Press, Cox Enterprises, Inc., Dairy Farm International Holdings Limited, ERGO Versicherungsgruppe AG, First Aviation Services Inc., General Mills, Inc., GlaxoSmithKline Plc, Griffith University, Hutchison 3G UK Limited, James Cook University, Johnson & Johnson, Koninklijke Philips Electronics N.V., Meredith Corporation, Metro AG, Monash University, PRA International, Queensland University of Technology, Rhodia, Schindler Holding Ltd., Siemens Healthcare, Telstra Corporation Limited, The University of Auckland, UCB S.A., Wolters Kluwer nv

To order this report:

Biotechnology Industry: Established and Emerging Biotech Clusters

Biotechnology Business News

More  Industry Analysis and Insights

Contact: Nicolas Bombourg
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Medical Policy Guideline for Trofile(TM) Established By Wellpoint, Inc.
2. New Canadian solar photovoltaic research network established; based at McMaster University
3. Simulated Environment Concepts Research Report to be Released - Domestic Sales Force Established
4. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
5. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
6. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
7. Abaxis, Inc. to Present at the Sidoti & Companys Seventh Annual West Coast Emerging Growth Institutional Investor Forum
8. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
9. Presenters Announced For MichBio Expos Emerging Business Showcase
10. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
11. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
Post Your Comments:
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):